In conclusion, inhibition of HMGB1 release or inhibition of HMGB1/TLR4/RAGE signaling pathway by HMGB1 inhibitors is beneficial for the treatment of depression (Tables 7–9). This evidence concerns the gene TLR4 and major depressive disorder.